Supernus Pharmaceuticals, Inc. Aktie News
43,10 €
0,47 %
vorgestern
L&S,
16. Januar, 22:53 Uhr
Index
Industrie
tracken
Supernus Pharmaceuticals, Inc. Aktie News
Positiv
Market Watch
●
3 Tage alt
The companies are projected to grow sales rapidly through 2027, and many of the stocks are expected to show double-digit increases this year.
Positiv
The Motley Fool
●
etwa ein Monat alt
Aristotle Capital Boston sold 503,122 shares of Supernus Pharmaceuticals in the third quarter. The move contributed to a net position change of about $10.9 million from the previous quarter.
Neutral
Seeking Alpha
●
etwa ein Monat alt
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual...
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthc...
Neutral
GlobeNewsWire
●
2 Monate alt
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.
Neutral
Seeking Alpha
●
2 Monate alt
Supernus Pharmaceuticals, Inc. ( SUPN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Jack Khattar - Founder, President, CEO, Secretary & Director Timothy Dec - Senior VP & CFO Conference Call Participants Peter Vozzo - Westwicke Partners, LLC Lin Tsai - Jefferies LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division David ...
Neutral
GlobeNewsWire
●
2 Monate alt
ROCKVILLE, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2025 and associated Company developments.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
